Q6VVW5
PR
Gene name |
Npr2 |
Protein name |
Atrial natriuretic peptide receptor 2 |
Names |
Atrial natriuretic peptide receptor type B, ANP-B, ANPR-B, NPR-B, Guanylate cyclase B, GC-B |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:230103 |
EC number |
4.6.1.2: Phosphorus-oxygen lyases |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q6VVW5
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q6VVW5-F1 | Predicted | AlphaFoldDB |
37 variants for Q6VVW5
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs238818347 | 59 | A>V | No | EVA | |
| rs3388673057 | 267 | T>S | No | EVA | |
| rs3388672971 | 339 | D>G | No | EVA | |
| rs3388661200 | 346 | Q>L | No | EVA | |
| rs3388681635 | 371 | R>L | No | EVA | |
| rs3388680668 | 373 | Y>F | No | EVA | |
| rs3388668402 | 419 | W>* | No | EVA | |
| rs3388676442 | 457 | A>T | No | EVA | |
| rs3388678406 | 481 | L>Q | No | EVA | |
| rs3388668971 | 486 | E>Q | No | EVA | |
| rs3388677910 | 515 | L>M | No | EVA | |
| rs3394298363 | 520 | R>G | No | EVA | |
| rs3388668338 | 521 | G>E | No | EVA | |
| rs3388677877 | 527 | L>F | No | EVA | |
| rs3388685458 | 541 | G>D | No | EVA | |
| rs3388681959 | 588 | D>Y | No | EVA | |
| rs3388679771 | 599 | C>S | No | EVA | |
| rs3388682474 | 628 | V>M | No | EVA | |
| rs3388676414 | 662 | D>N | No | EVA | |
| rs3388673020 | 670 | S>T | No | EVA | |
| rs3388668976 | 684 | K>E | No | EVA | |
| rs3388682509 | 717 | I>T | No | EVA | |
| rs3388677872 | 721 | S>N | No | EVA | |
| rs3388682550 | 725 | Y>F | No | EVA | |
| rs3394133967 | 753 | D>G | No | EVA | |
| rs3388678389 | 775 | E>K | No | EVA | |
| rs3412113985 | 815 | L>Q | No | EVA | |
| rs3388682496 | 821 | Q>E | No | EVA | |
| rs3388661265 | 828 | R>C | No | EVA | |
| rs3388678370 | 846 | L>S | No | EVA | |
| rs3388682547 | 869 | G>D | No | EVA | |
| rs3388683602 | 871 | T>A | No | EVA | |
| rs3388683602 | 871 | T>P | No | EVA | |
| rs3388685459 | 905 | V>A | No | EVA | |
| rs3388680721 | 980 | F>S | No | EVA | |
| rs3388673033 | 999 | I>T | No | EVA | |
| rs3388682533 | 1040 | Q>L | No | EVA |
No associated diseases with Q6VVW5
4 regional properties for Q6VVW5
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Protein kinase domain | 36 - 294 | IPR000719 |
| active_site | Serine/threonine-protein kinase, active site | 153 - 165 | IPR008271 |
| binding_site | Protein kinase, ATP binding site | 42 - 65 | IPR017441 |
| domain | Serine/threonine-protein kinase 10, catalytic domain | 23 - 314 | IPR042743 |
Functions
| Description | ||
|---|---|---|
| EC Number | 4.6.1.2 | Phosphorus-oxygen lyases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
9 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| GTP binding | Binding to GTP, guanosine triphosphate. |
| guanylate cyclase activity | Catalysis of the reaction: GTP = 3',5'-cyclic GMP + diphosphate. |
| hormone binding | Binding to an hormone, a naturally occurring substance secreted by specialized cells that affect the metabolism or behavior of cells possessing functional receptors for the hormone. Hormones may be produced by the same, or different, cell as express the receptor. |
| identical protein binding | Binding to an identical protein or proteins. |
| natriuretic peptide receptor activity | Combining with a natriuretic peptide and transmitting the signal to initiate a change in cell activity. |
| peptide hormone binding | Binding to a peptide with hormonal activity in animals. |
| peptide receptor activity | Combining with an extracellular or intracellular peptide to initiate a change in cell activity. |
| protein kinase activity | Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP. |
13 GO annotations of biological process
| Name | Definition |
|---|---|
| bone development | The process whose specific outcome is the progression of bone over time, from its formation to the mature structure. Bone is the hard skeletal connective tissue consisting of both mineral and cellular components. |
| cellular response to granulocyte macrophage colony-stimulating factor stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a granulocyte macrophage colony-stimulating factor stimulus. |
| cGMP biosynthetic process | The chemical reactions and pathways resulting in the formation of cyclic GMP, guanosine 3',5'-phosphate. |
| cGMP-mediated signaling | Any intracellular signal transduction in which the signal is passed on within the cell via cyclic GMP (cGMP). Includes production of cGMP, and downstream effectors that further transmit the signal within the cell. |
| meiotic cell cycle | Progression through the phases of the meiotic cell cycle, in which canonically a cell replicates to produce four offspring with half the chromosomal content of the progenitor cell via two nuclear divisions. |
| negative regulation of meiotic cell cycle | Any process that stops, prevents or reduces the rate or extent of progression through the meiotic cell cycle. |
| negative regulation of oocyte maturation | Any process that stops, prevents or reduces the frequency, rate or extent of oocyte maturation. |
| ossification | The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance. |
| positive regulation of cGMP-mediated signaling | Any process that increases the rate, frequency or extent of cGMP-mediated signaling. |
| protein phosphorylation | The process of introducing a phosphate group on to a protein. |
| receptor guanylyl cyclase signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| reproductive process | A biological process that directly contributes to the process of producing new individuals by one or two organisms. The new individuals inherit some proportion of their genetic material from the parent or parents. |
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
17 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| O02740 | GUCY2F | Retinal guanylyl cyclase 2 | Bos taurus (Bovine) | PR |
| P46197 | NPR2 | Atrial natriuretic peptide receptor 2 | Bos taurus (Bovine) | PR |
| P51841 | GUCY2F | Retinal guanylyl cyclase 2 | Homo sapiens (Human) | PR |
| Q02846 | GUCY2D | Retinal guanylyl cyclase 1 | Homo sapiens (Human) | PR |
| P20594 | NPR2 | Atrial natriuretic peptide receptor 2 | Homo sapiens (Human) | PR |
| P52785 | Gucy2e | Retinal guanylyl cyclase 1 | Mus musculus (Mouse) | PR |
| Q5SDA5 | Gucy2f | Retinal guanylyl cyclase 2 | Mus musculus (Mouse) | PR |
| P51840 | Gucy2e | Retinal guanylyl cyclase 1 | Rattus norvegicus (Rat) | PR |
| P18910 | Npr1 | Atrial natriuretic peptide receptor 1 | Rattus norvegicus (Rat) | PR |
| P51842 | Gucy2f | Retinal guanylyl cyclase 2 | Rattus norvegicus (Rat) | PR |
| P16067 | Npr2 | Atrial natriuretic peptide receptor 2 | Rattus norvegicus (Rat) | PR |
| Q09435 | gcy-1 | Receptor-type guanylate cyclase gcy-1 | Caenorhabditis elegans | PR |
| O16544 | gcy-19 | Receptor-type guanylate cyclase gcy-19 | Caenorhabditis elegans | PR |
| Q18331 | gcy-11 | Receptor-type guanylate cyclase gcy-11 | Caenorhabditis elegans | PR |
| Q10029 | gcy-2 | Receptor-type guanylate cyclase gcy-2 | Caenorhabditis elegans | PR |
| X5M8U1 | gcy-17 | Receptor-type guanylate cyclase gcy-17 | Caenorhabditis elegans | PR |
| Q23682 | gcy-5 | Receptor-type guanylate cyclase gcy-5 | Caenorhabditis elegans | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MALPSLLLVV | AALAGGVRPP | GARNLTLAVV | LPEHNLSYAW | AWPRVGPAVA | LAVEALGRAL |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PVDLRFVSSE | LDGACSEYLA | PLRAVDLKLY | HDPDLLLGPG | CVYPAASVAR | FASHWRLPLL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| TAGAVASGFA | AKNEHYRTLV | RTGPSAPKLG | EFVVTLHGHF | NWTARAALLY | LDARTDDRPH |
| 190 | 200 | 210 | 220 | 230 | 240 |
| YFTIEGVFEA | LQGSNLSVQH | QVYAREPGGP | EQATHFIRAN | GRIVYICGPL | EMLHEILLQA |
| 250 | 260 | 270 | 280 | 290 | 300 |
| QRENLTNGDY | VFFYLDVFGE | SLRAGPTRAT | GRPWQDNRTQ | EQAQALREAF | QTVLVITYRE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| PPNPEYQEFQ | NRLLIRARED | FGVELAPSLM | NLIAGCFYDG | ILLYAQVLNE | TIQEGGTRED |
| 370 | 380 | 390 | 400 | 410 | 420 |
| GLRIVEKMQG | RRYHGVTGLV | VMDKNNDRET | DFVLWAMGDL | DSGDFQPAAH | YSGAEKQIWW |
| 430 | 440 | 450 | 460 | 470 | 480 |
| TGRPIPWVKG | APPLDNPPCA | FDLDDPSCDK | TPLSTLAIVA | LGTGVTFIMF | GVSSFLIFRK |
| 490 | 500 | 510 | 520 | 530 | 540 |
| LMLEKELASM | LWRIRWEELQ | FGNSDRYHKG | AGSRLTLSLR | GSSYGSLMTA | HGKYQIFANT |
| 550 | 560 | 570 | 580 | 590 | 600 |
| GHFKGNVVAI | KHVNKKRIEL | TRQVLFELKH | MRDVQFNHLT | RFIGACIDPP | NICIVTEYCP |
| 610 | 620 | 630 | 640 | 650 | 660 |
| RGSLQDILEN | DSINLDWMFR | YSLINDLVKG | MAFLHNSIIS | SHGSLKSSNC | VVDSRFVLKI |
| 670 | 680 | 690 | 700 | 710 | 720 |
| TDYGLASFRS | TAEPDDSHAL | YAKKLWTAPE | LLSGNPLPTT | GMQKADVYSF | AIILQEIALR |
| 730 | 740 | 750 | 760 | 770 | 780 |
| SGPFYLEGLD | LSPKEIVQKV | RNGQRPYFRP | SIDRTQLNEE | LVLLMERCWA | QDPTERPDFG |
| 790 | 800 | 810 | 820 | 830 | 840 |
| QIKGFIRRFN | KEGGTSILDN | LLLRMEQYAN | NLEKLVEERT | QAYLEEKRKA | EALLYQILPH |
| 850 | 860 | 870 | 880 | 890 | 900 |
| SVAEQLKRGE | TVQAEAFDSV | TIYFSDIVGF | TALSAESTPM | QVVTLLNDLY | TCFDAIIDNF |
| 910 | 920 | 930 | 940 | 950 | 960 |
| DVYKVETIGD | AYMVVSGLPG | RNGQRHAPEI | ARMALALLDA | VSSFRIRHRP | HDQLRLRIGV |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| HTGPVCAGVV | GLKMPRYCLF | GDTVNTASRM | ESNGQALKIH | VSSTTKDALD | ELGCFQLELR |
| 1030 | 1040 | ||||
| GDVEMKGKGK | MRTYWLLGEQ | KGPPGLL |